Department of Human Physiology, Medical University of Lublin, Lublin, Poland.
Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Lublin, Poland.
Med Sci Monit. 2022 Jul 13;28:e936534. doi: 10.12659/MSM.936534.
BACKGROUND Calprotectin (S100A8/A9 or myeloid-related protein 8/14) is a heterodimeric S100 complex expressed in leukocytes. Calprotectin participates in development of the inflammatory response by binding to receptors for advanced glycation end-products (RAGE) and Toll-like receptors (TLR). The clinical activity of systemic lupus erythematosus (SLE) is evaluated using the Systemic Lupus International Collaborating Clinics (SLICC) criteria and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). This Polish single-center case-control study aimed to evaluate serum levels of calprotectin as a rapid diagnostic biomarker of SLE (59 patients with SLE were compared with 52 healthy controls). MATERIAL AND METHODS Calprotectin concentration was measured with the use of enzyme-linked immunosorbent assay (ELISA). The SLE activity of the patients was assessed by the SLEDAI scale. Statistical analysis of the results was carried out using MedCalc 15.8 software. P<0.05 was considered statistically significant. RESULTS A significantly higher concentration of calprotectin was found in the study group compared to the control group (medians: 3.11 vs 2.45 ng/ml; P=0.0013). We found that calprotectin has high sensitivity (89.83%) and specificity (53.85%) in differentiating between SLE patients and healthy volunteers. We found that calprotectin has very high sensitivity (100%) and specificity (82.46%) in detection of patients with moderate and severe SLE assessed using SLEDAI. CONCLUSIONS Consistent with previous studies, serum calprotectin level was revealed to have potential as a rapid diagnostic biomarker of disease activity in patients with SLE.
钙卫蛋白（S100A8/A9 或髓系相关蛋白 8/14）是一种表达于白细胞中的异二聚体 S100 复合物。钙卫蛋白通过与晚期糖基化终产物受体（RAGE）和 Toll 样受体（TLR）结合，参与炎症反应的发展。系统性红斑狼疮（SLE）的临床活动通过使用系统性红斑狼疮国际合作临床（SLICC）标准和系统性红斑狼疮疾病活动指数（SLEDAI）进行评估。这项波兰单中心病例对照研究旨在评估血清钙卫蛋白水平作为 SLE 的快速诊断生物标志物（将 59 例 SLE 患者与 52 例健康对照进行比较）。材料和方法：使用酶联免疫吸附试验（ELISA）测量钙卫蛋白浓度。使用 SLEDAI 量表评估患者的 SLE 活动。使用 MedCalc 15.8 软件对结果进行统计分析。P<0.05 被认为具有统计学意义。结果：与对照组相比，研究组钙卫蛋白浓度明显升高（中位数：3.11 vs 2.45 ng/ml；P=0.0013）。我们发现，钙卫蛋白在区分 SLE 患者和健康志愿者方面具有很高的敏感性（89.83%）和特异性（53.85%）。我们发现，钙卫蛋白在检测 SLEDAI 评估的中重度 SLE 患者时具有非常高的敏感性（100%）和特异性（82.46%）。结论：与先前的研究一致，血清钙卫蛋白水平被揭示为 SLE 患者疾病活动的潜在快速诊断生物标志物。
